Advertisement
ALNY or BIIB or BMY
Which Stock Would AI Choose? Alnylam Pharmaceuticals (ALNY) vs. Biogen (BIIB) vs. Bristol-Myers Squibb (BMY) Stock Comparison
Key Takeaways
- ALNY shares have faced recent pressure with a YTD decline of about 19%, despite long-term gains and positive regulatory news like UK NICE recommendation for its heart drug.
- BIIB shows stronger momentum, up around 6% YTD, bolstered by Q4 earnings beats and 10 Phase 3 programs nearing readouts.
- BMY leads YTD performance at 13%, driven by growth portfolio including Reblozyl surpassing $2.3B in annualized sales and recent FDA approval for Sotyktu in psoriatic arthritis.
- Valuation contrasts: ALNY P/E ~137, no dividend; BIIB P/E ~21; BMY P/E ~17 with 4.2% yield.
- All three operate in biotech with neurology/cardio focus, but BMY offers scale (market cap ~$123B) vs. ALNY (~$43B) and BIIB (smaller).
- Recent market activity highlights BMY's stability amid volatility in smaller biotech peers.
Introduction
This stock comparison examines ALNY, BIIB, and BMY, three biopharmaceutical leaders in neurology, rare diseases, and cardiovascular therapies. Investors tracking biotech relative performance may find value here, as these firms navigate pipeline catalysts, earnings momentum, and sector headwinds like generic competition. Amid recent market shifts, their contrasting YTD returns, valuations, and growth drivers offer insights into risk-reward trade-offs for diversified portfolios focused on long-term innovation in high-unmet-need areas.
ALNY Overview and Recent Performance
Alnylam Pharmaceuticals (ALNY) pioneers RNA interference (RNAi) therapeutics for rare and prevalent diseases, with key products like Amvuttra for ATTR amyloidosis. In recent market activity, shares have declined around 19% YTD and 9% over the past month, reflecting broader biotech volatility despite a 31% one-year gain. Sentiment has been influenced by a 30% three-month pullback, though longer-term holders benefit from 125% five-year returns. Positive catalysts include the UK's NICE recommendation for its heart disease drug and a $1.13B deal with Tenaya Therapeutics for cardiovascular targets, signaling pipeline expansion. Trading at ~$321 with a market cap of $43B and P/E of 137, ALNY remains growth-oriented without dividends.
BIIB Overview and Recent Performance
Biogen (BIIB) focuses on neurology and immunology, with multiple sclerosis therapies and emerging Alzheimer's treatments like Leqembi. Recent weeks saw shares gain ~18% over 30 days and 6% YTD, supported by Q4 earnings and revenue beats ($2.28B vs. expected $2.21B). CEO comments highlight a "new era of growth" with 10 Phase 3 programs nearing readouts, offsetting legacy MS drug declines. At ~$185, market cap aligns smaller than peers, P/E ~21, with 2026 EPS guidance of $15.25-$16.25. Momentum stems from pipeline progress in lupus and stroke, though longer-term three-year returns lag.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY) delivers oncology, immunology, and cardiovascular drugs, with a diversified growth portfolio offsetting legacy declines. Shares rose 13% YTD and 11% monthly, trading at ~$60 with $123B market cap, P/E 17, and 4.2% yield. Recent performance reflects FDA approval for Sotyktu in psoriatic arthritis and Reblozyl's $2.3B annualized sales milestone amid strong MDS anemia uptake. Positive Phase 2 data in alpha-thalassemia further bolsters sentiment, with growth brands like Opdivo and Camzyos driving 16% portfolio expansion despite patent cliffs.
Trending AI Robots
Tickeron's Trending AI Robots page curates over 25 high-performing AI trading bots from hundreds available, scanning thousands of tickers for those best suited to current volatility and sectors like aerospace, energy, and semiconductors. These bots employ diverse ML strategies across 5min-60min timeframes, trading 1-25 tickers with stats like 13%-215% annualized returns (e.g., +215% on USAR/SMR/CIFR), 52%-94% win rates (e.g., 94% on BIB), and profit factors up to 25.8. Top examples include AeroDefense ITA (+32%, 80% win, 60min) and multi-ticker semi/oil (+134%, 62% win, 15min). Explore these adaptive tools for real-time copy trading signals tailored to market conditions.
Head-to-Head Comparison
ALNY, BIIB, and BMY share biotech exposure in neurology/cardio but diverge in scale and stability. Business models: ALNY's RNAi innovation targets rare diseases; BIIB emphasizes neurology pipeline; BMY leverages broad pharma diversification. Growth drivers favor BMY's Reblozyl/Sotyktu vs. ALNY's Amvuttra deals. Recent momentum: BMY strongest YTD, ALNY weakest. Risks: Biotech volatility hits ALNY/BIIB harder; BMY faces legacy erosion. Valuation sensitivity: High P/E for ALNY signals growth premium; BMY's yield appeals to income seekers. Sentiment tilts toward BMY's consistency.
Tickeron AI Verdict
Tickeron's AI currently favors BMY for its superior trend consistency, YTD outperformance, robust growth portfolio catalysts like Sotyktu approval and Reblozyl momentum, plus attractive valuation and dividend stability relative to peers. While BIIB's pipeline readouts offer upside and ALNY holds long-term potential, BMY's scale and lower risk profile position it probabilistically stronger in the near-term market environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green whileBIIB’s FA Score has 1 green FA rating(s), and BMY’s FA Score reflects 2 green FA rating(s).
- ALNY’s FA Score: 1 green, 4 red.
- BIIB’s FA Score: 1 green, 4 red.
- BMY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 2 TA indicator(s) are bullish while BIIB’s TA Score has 4 bullish TA indicator(s), and BMY’s TA Score reflects 6 bullish TA indicator(s).
- ALNY’s TA Score: 2 bullish, 7 bearish.
- BIIB’s TA Score: 4 bullish, 5 bearish.
- BMY’s TA Score: 6 bullish, 4 bearish.
Price Growth
ALNY (@Biotechnology) experienced а -3.87% price change this week, while BIIB (@Pharmaceuticals: Major) price change was +2.53% , and BMY (@Pharmaceuticals: Major) price fluctuated +2.64% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was +7.89%.
Reported Earning Dates
ALNY is expected to report earnings on Apr 30, 2026.
BIIB is expected to report earnings on Apr 29, 2026.
BMY is expected to report earnings on Apr 30, 2026.
Industries' Descriptions
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ALNY | BIIB | BMY | |
| Capitalization | 41.3B | 26B | 123B |
| EBITDA | 631M | 2.6B | 15.2B |
| Gain YTD | -22.127 | 0.773 | 14.032 |
| P/E Ratio | 132.90 | 20.18 | 17.39 |
| Revenue | 3.71B | 9.89B | 48.2B |
| Total Cash | 2.91B | 3.82B | N/A |
| Total Debt | 1.28B | 6.58B | 47.1B |
ALNY | BIIB | BMY | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 13 | 14 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 89 Overvalued | 41 Fair valued | |
PROFIT vs RISK RATING 1..100 | 53 | 100 | 81 | |
SMR RATING 1..100 | 15 | 78 | 23 | |
PRICE GROWTH RATING 1..100 | 62 | 47 | 21 | |
P/E GROWTH RATING 1..100 | 100 | 14 | 66 | |
SEASONALITY SCORE 1..100 | 50 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (41) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (89) in the Biotechnology industry, and is somewhat better than the same rating for ALNY (94) in the Biotechnology industry. This means that BMY's stock grew somewhat faster than BIIB’s and somewhat faster than ALNY’s over the last 12 months.
ALNY's Profit vs Risk Rating (53) in the Biotechnology industry is in the same range as BMY (81) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for BIIB (100) in the Biotechnology industry. This means that ALNY's stock grew similarly to BMY’s and somewhat faster than BIIB’s over the last 12 months.
ALNY's SMR Rating (15) in the Biotechnology industry is in the same range as BMY (23) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for BIIB (78) in the Biotechnology industry. This means that ALNY's stock grew similarly to BMY’s and somewhat faster than BIIB’s over the last 12 months.
BMY's Price Growth Rating (21) in the Pharmaceuticals Major industry is in the same range as BIIB (47) in the Biotechnology industry, and is somewhat better than the same rating for ALNY (62) in the Biotechnology industry. This means that BMY's stock grew similarly to BIIB’s and somewhat faster than ALNY’s over the last 12 months.
BIIB's P/E Growth Rating (14) in the Biotechnology industry is somewhat better than the same rating for BMY (66) in the Pharmaceuticals Major industry, and is significantly better than the same rating for ALNY (100) in the Biotechnology industry. This means that BIIB's stock grew somewhat faster than BMY’s and significantly faster than ALNY’s over the last 12 months.
| ALNY | BIIB | BMY | |
|---|---|---|---|
| RSI ODDS (%) | N/A | N/A | 3 days ago 42% |
| Stochastic ODDS (%) | 3 days ago 63% | 3 days ago 65% | 3 days ago 48% |
| Momentum ODDS (%) | 3 days ago 65% | 3 days ago 57% | 3 days ago 45% |
| MACD ODDS (%) | 3 days ago 72% | 3 days ago 72% | 3 days ago 55% |
| TrendWeek ODDS (%) | 3 days ago 64% | 3 days ago 58% | 3 days ago 52% |
| TrendMonth ODDS (%) | 3 days ago 69% | 3 days ago 71% | 3 days ago 54% |
| Advances ODDS (%) | 6 days ago 76% | 5 days ago 57% | 3 days ago 54% |
| Declines ODDS (%) | 3 days ago 66% | 10 days ago 72% | 7 days ago 53% |
| BollingerBands ODDS (%) | 3 days ago 87% | 3 days ago 46% | 3 days ago 48% |
| Aroon ODDS (%) | 3 days ago 71% | 3 days ago 64% | 3 days ago 55% |
Advertisement